Article thumbnail

Peripheral Blood Signatures of Lead Exposure

By Heather G. LaBreche, Sarah K. Meadows, Joseph R. Nevins and John P. Chute
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1996). A
  2. (2005). A critical review of biomarkers used for monitoring human exposure to lead: advantages, limitations, and future needs.
  3. (2010). A pathway-based classification of human breast cancer.
  4. (1997). Augmentation of protein kinase C activity and liver cell proliferation in lead nitrate-treated rats.
  5. (2006). Below background levels of blood lead impact cytokine levels in male and female mice.
  6. (2009). Bergamaschi A
  7. (2002). Blood lead levels and mortality.
  8. (1995). Cancer and occupational exposure to inorganic lead compounds: a meta-analysis of published data.
  9. (1990). Cell proliferation and promotion of rat liver carcinogenesis: different effect of hepatic regeneration and mitogen induced hyperplasia on the development of enzyme-altered foci.
  10. (1974). Cell proliferation in mouse kidney induced by lead. I. Synthesis of deoxyribonucleic acid.
  11. (2010). Diagnosis of partial body radiation exposure in mice using peripheral blood gene expression profiles.
  12. (2002). Effects of per os lead acetate administration on mouse hepatocyte survival.
  13. (2010). Environmental toxicogenomics: a post-genomic approach to analysing biological responses to environmental toxins.
  14. (2008). Gene expression signatures of radiation response are specific, durable and accurate in mice and humans.
  15. (2007). Gene expression signatures that predict radiation exposure in mice and humans.
  16. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
  17. (2009). Genetical toxicogenomics in Drosophila identifies master-modulatory loci that are regulated by developmental exposure to lead.
  18. (2010). Genotoxic effects of lead: an updated review.
  19. (2007). GSEA-P: a desktop application for Gene Set Enrichment Analysis.
  20. (2010). Impact of developmental lead exposure on splenic factors.
  21. (1990). Implications of new data on lead toxicity for managing and preventing exposure.
  22. (2001). In vitro toxicology of heavy metals using mammalian cells: an overview of collaborative research data.
  23. (2000). Induction of vascular endothelial growth factor in human astrocytes by lead. Involvement of a protein kinase C/activator protein-1 complex-dependent and hypoxia-inducible factor 1-independent signaling pathway.
  24. (2006). Inorganic and organic lead compounds.
  25. (2001). Inorganic lead stimulates DNA synthesis in human astrocytoma cells: role of protein kinase Calpha.
  26. (2007). Interpreting and Managing Blood Lead Levels ,10 mg/dL in Children and Reducing Childhood Exposures to Lead: Recommendations of CDC’s Advisory Committee on Childhood Lead Poisoning Prevention.
  27. (2000). Lead and cancer in humans: where are we now?
  28. (1983). Lead and liver cell proliferation. Effect of repeated administrations.
  29. (2003). Lead neurotoxicity in children: basic mechanisms and clinical correlates.
  30. (1999). Lead stimulates lymphocyte proliferation through enhanced T cell-B cell interaction.
  31. (2003). Lead-induced endoplasmic reticulum (ER) stress responses in the nervous system.
  32. (1994). Low-level lead exposure and cognitive function in children.
  33. (2001). Microarray analysis of differential gene expression in lead-exposed astrocytes.
  34. (1992). Mutagenesis and comutagenesis by lead compounds.
  35. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies.
  36. (1987). Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl 7: 1–
  37. (2003). Pb2+-induced toxicity is associated with p53-independent apoptosis and enhanced by glutamate in GT1-7 neurons.
  38. (2010). Pb2+: an endocrine disruptor in Drosophila?
  39. (1993). Perspectives on lead toxicity.
  40. (2007). Posttranscriptional inhibition of interferon-gamma production by lead.
  41. (2001). Predicting the clinical status of human breast cancer by using gene expression profiles.
  42. (2002). Recovery of adult oligodendrocytes is preceded by a "lag period" accompanied by upregulation of transcription factors expressed in developing young cells.
  43. (2003). Report on Carcinogens, Eleventh Edition.
  44. (1994). Role of DNA repair inhibition in lead- and cadmium-induced genotoxicity: a review. Environ Health Perspect
  45. (1995). Stimulatory effect of lead on the proliferation of cultured vascular smooth-muscle cells.
  46. (1989). The effect of lead on protein and DNA metabolism of normal and lead-adapted rat kidney cells in culture.
  47. (1998). The genetic effects of environmental lead.
  48. (2003). Toxicogenomic approach for assessing toxicant-related disease.
  49. (2003). Toxicogenomics: challenges and opportunities.
  50. (2007). Toxicological Profile for Lead.In Book Toxicological Profile for Lead
  51. (1977). Toxicological properties of lead.
  52. (2008). Very low lead exposures and children’s neurodevelopment.